Abstract 18P
Background
High neutrophil to lymphocyte ratio may reflect the key role of systemic inflammation in enhancing angiogenesis, tumor growth and development of metastasis The role of lymphocytes cells in cancer control is exemplified by the strong association between high densities of tumor-infiltrating lymphocytes and better responses to both, cytotoxic treatments and outcome in patients with breast cancer.
Methods
A total number of files reviewed is 1167 files and a total of 102 breast cancer patients included in this study with histologically proven early stage (T1–2, N0–1, non-metastatic) breast cancer treated in Babylon Oncology Center from January 2009 to September 2014 were considered for this retrospective study. The following data were collected from patient file: age, date of diagnosis, date of recurrence and/or metastasis, follow up period, histological tumor type, tumor size, tumor-node-metastasis stage, expression of estrogen and/or progesterone receptor, HER-2-neu status, metastasis site and with inclusion criteria of Tumor stage up to stage IIA (T1-T2, N0/ T1, N1), follow up for at least 36 months and pre-treatment CBC with differential count.
Results
With mean age of 50.4 ± 11.7 years and minimum follow up 40 months, the overall median DFS was 62 months with 5 – years DFS of 52.5%, stage N0 show significant better DFS compared to stage N1 (P value 0.004), also patients with positive hormonal status show significant better DFS compared to negative hormonal status (P value 0.029), NLR has significant outcome on DFS when increased the ratio leading to declining in DFS (P value 0.006), NLR fair specificity (76.9%) with lower sensitivity (62.2%), with optimal cut point of > 2.194 to predict DFS with better DFS about 16 months (P value 0.0004), and Hazard Ration is 2.5 (P value 0.007), in univariate analysis the significant Hazard Ratio are NLR, N staging and Hormonal status while in multivariate analysis shows only NLR Hazard Ratio with (0.012 P value). In our study PLR neither sensitive nor specific with non-significant P value so it will not be consider as a prognostic index.
Conclusions
Elevated NLR is strongly associated with poor disease free survival of breast cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Iraqi Board for Medical Specialities.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
504P - A single center report for safety and efficacy of CT-707 in Chinese patients with advanced, anaplastic lymphoma kinase-rearranged non-small cell lung cancer or other tumours
Presenter: Peng Song
Session: Poster display session
Resources:
Abstract
519P - Initial results of lung cancer genomic screening project for individualized medicine in Asia: LC-SCRUM-Asia
Presenter: Chih-Hsi Kuo
Session: Poster display session
Resources:
Abstract
521P - A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
Presenter: Keisuke Baba
Session: Poster display session
Resources:
Abstract
526P - A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Li Chu
Session: Poster display session
Resources:
Abstract
499P - Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected by circulating tumour DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients in Hong Kong
Presenter: Oscar Siu Hong Chan
Session: Poster display session
Resources:
Abstract
489P - Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study
Presenter: Maximilian J. Hochmair
Session: Poster display session
Resources:
Abstract
509P - Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial
Presenter: Andrea Camerini
Session: Poster display session
Resources:
Abstract
500P - Clinico-molecular characteristics of Chinese primary non-small cell lung cancer patients with compound EGFR mutations
Presenter: Jianchun Duan
Session: Poster display session
Resources:
Abstract
527P - A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing
Presenter: Xingliang Li
Session: Poster display session
Resources:
Abstract
481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
Presenter: Toshihide Yokoyama
Session: Poster display session
Resources:
Abstract